Omega-3 Fatty Acids to Combat Sarcopenia

Completed · Phase 1

Conditions studied: Sarcopenia

In brief

The purpose of this study is to determine how omega-3 fatty acids influence muscle protein metabolism and mitochondrial physiology in the context of human aging.

Key facts

Study ID

NCT02103842

Run by

Mayo Clinic

People needed

24

Starts

2014-03-01

Expected to finish

2015-07-01

Last updated by the study team

2015-12-24

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-35 or 65-85 years

You may not qualify if…

• Current use of omega-3 nutritional supplements
• Fasting plasma glucose ≥126 mg/dL
• Active coronary artery disease
• Participation in structured exercise (>3 times per week for 30 minutes or longer)
• Smoking
• Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)
• Renal failure (serum creatinine > 1.5mg/dl)
• Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L)
• Anti-coagulant therapy (warfarin/heparin)
• INR >3
• Use of systemic glucocorticoids
• Chronic use of NSAIDS or aspirin
• Pregnancy or breastfeeding
• Alcohol consumption greater than 2 glasses/day
• Hypothyroidism
• Fish or shellfish allergy

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.